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ABSTRACT Candida glabrata is the second most common Candida species causing
disseminated infection, after C. albicans. C. glabrata is intrinsically less susceptible to
the widely used azole antifungal drugs and quickly develops secondary resistance.
Resistance typically relies on drug efﬂux with transporters regulated by the transcrip-
tion factor Pdr1. Gain-of-function (GOF) mutations in PDR1 lead to a hyperactive
state and thus efﬂux transporter upregulation. Our laboratory has characterized a
collection of C. glabrata clinical isolates in which azole resistance was found to cor-
relate with increased virulence in vivo. Contributing phenotypes were the evasion of
adhesion and phagocytosis by macrophages and an increased adhesion to epithelial
cells. These phenotypes were found to be dependent on PDR1 GOF mutation and/or
C. glabrata strain background. In the search for the molecular effectors, we found
that PDR1 hyperactivity leads to overexpression of speciﬁc cell wall adhesins of
C. glabrata. Further study revealed that EPA1 regulation, in particular, explained the
increase in adherence to epithelial cells. Deleting EPA1 eliminates the increase in ad-
herence in an in vitro model of interaction with epithelial cells. In a murine model of
urinary tract infection, PDR1 hyperactivity conferred increased ability to colonize the
bladder and kidneys in an EPA1-dependent way. In conclusion, this study establishes
a relationship between PDR1 and the regulation of cell wall adhesins, an important
virulence attribute of C. glabrata. Furthermore, our data show that PDR1 hyperactiv-
ity mediates increased adherence to host epithelial tissues both in vitro and in vivo
through upregulation of the adhesin gene EPA1.
IMPORTANCE Candida glabrata is an important fungal pathogen in human diseases
and is also rapidly acquiring drug resistance. Drug resistance can be mediated by
the transcriptional activator PDR1, and this results in the upregulation of multidrug
transporters. Intriguingly, this resistance mechanism is associated in C. glabrata with
increased virulence in animal models and also with increased adherence to speciﬁc
host cell types. The C. glabrata adhesin gene EPA1 is a major contributor of viru-
lence and adherence to host cells. Here, we show that EPA1 expression is controlled
by PDR1 independently of subtelomeric silencing, a known EPA1 regulation mecha-
nism. Thus, a relationship exists between PDR1, EPA1 expression, and adherence to
host cells, which is critical for efﬁcient virulence. Our results demonstrate that acqui-
sition of drug resistance is beneﬁcial for C. glabrata in fungus-host relationships.
These ﬁndings further highlight the challenges of the therapeutic management of
C. glabrata infections in human patients.
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Candida glabrata is an opportunistic pathogen that is able to cause invasive infectionin susceptible patients. Because C. glabrata is an opportunistic pathogen, host
susceptibility is critical to initiate active infection, and over the last half century, the
human population at risk has increased (1). This trend is based on an increased number
of immunosuppressed patients. Several factors, such as the occurrence of different
cancers, the use of organ transplants, the persistence of the AIDS pandemic, the use of
broad-spectrum antibiotics, and the expansion of the elderly population, have contrib-
uted to the increase of this patient population (2). C. glabrata deploys several distinct
factors to infect its host. C. glabrata is less pathogenic than Candida albicans (3);
however, it is able to persist in experimental infection models for long periods by
eliciting only mild immune responses (4, 5). An important virulence attribute of
C. glabrata is its capacity to adhere to host tissues. The genome of C. glabrata contains
a high number of genes (around 60 in the CBS138 genome) encoding predicted
glycosylphosphatidylinositol (GPI)-anchored adhesin-like cell wall proteins (6). Adhesins
of C. glabrata are distributed in several groups. The EPA (epithelial adhesion) subfamily
is crucial for interaction with host cells. EPA1 is the ﬁrst member of this family and was
identiﬁed by Cormack et al. (7) as a major mediator of adherence to epithelial cells.
Interestingly, a majority of C. glabrata adhesin genes exhibit subtelomeric locations and
are thus under the control of transcriptional silencing by chromatin-based and NAD-
dependent regulation mechanisms (8). Since C. glabrata is a nicotinic acid (NA) auxo-
troph, NAD-limiting environments release adhesin genes from transcriptional repres-
sion when they have a subtelomeric location. Interestingly, the urinary tract is NAD
poor and is thus a favorable host environment for adhesin expression. As a matter of
fact, urinary tract infections (UTIs) caused by C. glabrata are very common (8).
In recent years, C. glabrata has emerged as an important fungal pathogen in many
regions of the world (9). It is believed that antifungal drug usage and the emergence
of antifungal drug-resistant C. glabrata isolates are partially responsible for this obser-
vation. Currently available antifungal agents for treatment of candidiasis are azoles,
candins, and polyenes. Azoles and polyenes such as amphotericin interfere with sterols
in these species at different levels. While azoles inhibit an important step in ergosterol
biosynthesis (14-lanosterol demethylation), amphotericin B forms a complex with
ergosterol which compromises fungal viability. Candins target cell wall biosynthesis by
inhibiting fungus-speciﬁc glucan synthesis. C. glabrata is intrinsically less susceptible to
azole antifungals than is C. albicans (10). In addition, when exposed to this class of
agents, C. glabrata rapidly develops resistance. It is believed that 20% of clinical isolates
are azole resistant (11). Most azole-resistant isolates upregulate ATP-binding cassette
(ABC) transporter genes, including C. glabrata CDR1 (CgCDR1) and CgCDR2, which are
important transporters for the development of azole resistance (12). This upregulation
is mediated by PDR1, a transcriptional activator of the zinc cluster transcription factor
family with a Zn(2)Cys(6) domain. Mutations in PDR1 are called gain-of-function (GOF)
mutations, since they are responsible for constitutive high expression of ABC trans-
porters in resistant isolates. Multiple GOF mutations have been described, and they
occur at different functional domains of the protein (12–15). PDR1 interacts with the
Mediator complex which bridges the activator and the transcriptional machinery in
C. glabrata (16). Pdr1 regulates other genes in C. glabrata due to the presence of a
pleiotropic drug resistance element (PDRE), a predicted Pdr1 binding target sequence,
in the promoters of target genes (17). PDR1 GOF mutations not only regulate ABC
transporter genes but also target other genes responsible for other cellular processes.
Strikingly, recent reports document increased proportions of multidrug-resistant
C. glabrata isolates (i.e., isolates resistant to at least two different classes of agents)
(18–20). It has been established that about 3 to 11% of azole-resistant isolates in the
United States also exhibit candin resistance (21).
The selection of drug-resistant isolates by drug exposure can have a cost (or ﬁtness
cost) for the yeast. The cost of antifungal resistance is that strains may be less
competitive than wild-type isolates, especially when the drug selection is removed. This
potential decrease in ﬁtness may indeed compromise their virulence. In C. glabrata,
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however, a few studies have addressed the relationship between acquisition of drug
resistance and changes in virulence traits and found evidence of increased virulence. As
reported by Poláková et al. (22) and Ahmad et al. (23), C. glabrata can form minichro-
mosomes containing genes involved in drug resistance while colonizing the human
host, which may selectively favor the expansion of this yeast in vivo. The effects of PDR1
GOF mutations on in vivo ﬁtness and on virulence have been addressed in C. glabrata.
It was discovered that PDR1 GOF mutations, in addition to their role as mediators of
azole resistance, could enhance virulence of C. glabrata compared to wild-type isolates
in mice (12). Enhanced virulence observed in mice was accompanied not only by
elevated fungal loads in infected organ but also by treatment failure with azoles.
Moreover, the change in virulence was paralleled with gain of in vivo ﬁtness of strains
carrying PDR1 GOF mutations. The dogma that development of drug resistance is
associated with ﬁtness costs was therefore challenged by the results of Ferrari et al. (12),
given that azole resistance had rather a ﬁtness beneﬁt in vivo. CgCDR1, the ABC
transporter involved in azole resistance, and the open reading frame (ORF)
CAGL0M12947g (PUP1, or PDR1-upregulated gene) are commonly upregulated by PDR1
GOF mutations, and this effect was thought to explain enhanced virulence (24). While
deletions of CgCDR1 and PUP1 decreased virulence of C. glabrata in a mouse model of
infection, PDR1-independent overexpression resulted in intermediate virulence pheno-
types. This suggested that other C. glabrata factors were responsible for the gain of
virulence observed in drug-resistant isolates.
To gain insights about these additional factors, we further addressed the role of
PDR1 mutations in the interaction with several mammalian cell types, including murine
bone marrow-derived macrophages (BMDMs), human acute monocytic leukemia cell
line (THP-1)-derived macrophages, and different epithelial cell lines (25). We showed
that, interestingly, PDR1 GOF mutations led to decreased adherence to macrophages
and to decreased uptake by the same cells. The interaction with epithelial cells
revealed, however, an opposite trend. This suggested that PDR1 GOF mutations may
help C. glabrata to colonize epithelial host cells by increasing adherence to epithelial
cell layers. These data highlighted that PDR1 GOF mutations modulate the interaction
with host cells with the consequence of increasing virulence.
Here, we show that speciﬁc adhesion attributes of C. glabrata are regulated by PDR1.
Among them, the adhesin gene EPA1 contributes to enhanced adhesion to epithelial
mammalian cell lines when PDR1 mutations are causing azole resistance. This PDR1-
mediated effect may help this yeast species to be a more efﬁcient pathogen.
RESULTS
Modulation of the interaction with host cells is PDR1 GOF mutation and C.
glabrata strain dependent. In a previous report, we showed that PDR1 hyperactivity
in C. glabratamediates evasion from phagocytosis by murine and human macrophages
(25). This was reproduced across three different PDR1 GOF mutations (L280F, R376W,
and T588A) expressed in the azole-susceptible C. glabrata oropharyngeal clinical isolate
DSY562. Surprisingly, we also found that the GOF mutation L280F led to increased
adherence of DSY562 to three different epithelial cell lines (25). To follow up, we ﬁrst
addressed the reproducibility of these effects in different C. glabrata strain back-
grounds, including the reference strain CBS138 (ATCC 2001), whose genome was
sequenced and is publicly available (26); BG2, a well-known genetic background used
in several studies (7, 8, 27, 28); and DSY2235, another azole-susceptible oropharyngeal
clinical isolate from our strain collection (12). We introduced the same PDR1 alleles (the
wild-type PDR1 allele from clinical isolate DSY562, PDR1WT, and the hyperactive allele
from matched isolate DSY565, PDR1L280F) in these three additional C. glabrata strains
and repeated competition phagocytosis assays using RAW 264.7 macrophage-like cells.
Mixed suspensions of a given genetic background bearing either PDR1WT or PDR1L280F
(and additionally expressing either green ﬂuorescent protein [GFP] or red ﬂuorescent
protein [RFP], in order to distinguish between strains) were used to inoculate the
macrophage cultures. Representative microscopy pictures are shown in Fig. S2 in the
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supplemental material. Our results conﬁrmed the differences between DSY562 express-
ing the two alleles that were previously observed using primary murine macrophages
and THP-1-derived human macrophages (Fig. 1A). However, this effect depended on
the C. glabrata genetic background and was reproduced only by strain DSY2235 and
not by CBS138 or BG2 (Fig. 1A). We next tested the adherence of the constructed strains
to CHO-Lec2 epithelial cells and found that the increase in adherence was reproduced
in all tested strain backgrounds (Fig. 1B). Our previous work showed that other tested
PDR1 alleles with GOF mutations R376W and T588A expressed in DSY562 reproduced
the differences in the interaction with macrophages (25). Here, we addressed whether
they also mediated increased adherence to CHO-Lec2 cells. Our results indicate that
these GOF mutations could mediate a similar increase in adherence when expressed in
DSY2235 (Fig. 1D) but not in DSY562 (Fig. 1C).
PDR1 hyperactivity leads to adhesin gene overexpression. In light of these
PDR1-mediated changes in the interaction of C. glabrata with mammalian innate
immune cells and epithelial cells, we reasoned that PDR1might regulate the expression
of cell wall proteins with a role in adherence to host cells. We combined information
FIG 1 Influence of PDR1 hyperactivity on the interaction of C. glabrata with mammalian host cells. Log-phase C. glabrata suspensions containing a 1:1
mix of two strains with either the PDR1WT or the PDR1L280F alleles were added to mammalian cell cultures. (A) Mixed yeast suspensions, labeled by
expression of GFP or RFP, were added to preconfluent RAW 264.7 macrophage-like cells and incubated for 1 h at 37°C in a humid atmosphere with 5%
CO2. The cultures were then washed to remove noninternalized yeasts, and percent internalization ratios (PIRs; percentage of each of the two yeast strains
in the total number of yeasts) were determined. Test strains were constructed on four different genetic backgrounds: DSY562 (VSY103 to VSY106), CBS138
(VSY239 to VSY243), BG2 (VSY154, VSY155, VSY159, and VSY160), and DSY2235 (VSY231 to VSY234). (B) Mixed yeast suspensions of strains bearing the
PDR1WT or the PDR1L280F alleles in different C. glabrata strain backgrounds were added to confluent CHO-Lec2 epithelial cell monolayers and incubated
for 30 min at 37°C in a humid atmosphere with 5% CO2. The cultures were then washed four or five times to remove nonadherent yeasts, the epithelial
cells were selectively lysed, and dilutions of the resulting yeast suspensions were plated on solid medium with or without fluconazole (to distinguish
between azole-susceptible and azole-resistant yeast strains). Results are presented as CFU counts relative to the strain bearing the PDR1WT allele (set to
100%). Test strains were constructed on four different genetic backgrounds: DSY562 (VSY101 and VSY102), CBS138 (VSY236 and VSY237), BG2 (VSY149
and VSY150), and DSY2235 (VSY229 and VSY230). (C) Influence of two additional PDR1 alleles on adherence of strain DSY562 (derived strains VSY101,
VSY102, VSY134, and VSY135) to epithelial cells determined as described for the experiment in panel B. (D) Influence of two additional PDR1 alleles on
adherence of strain DSY2235 (derived strains VSY229, VSY230, VSY277, and VSY278) to epithelial cells determined as described for the experiment in
panel B. Results are means  standard deviations of a minimum of three independent experiments. Pairwise comparisons were performed using
unpaired-sample two-tailed Mann-Whitney U tests. Bonferroni-adjusted P values of <0.05 were considered significant, and asterisks represent P value
ranges (*, P value of <0.05; **, P value of <0.01; ***, P value of < 0.001). WT, wild type; ns, not significant.
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from a previous genome-wide microarray study of PDR1 hyperactivity in DSY562
performed in our laboratory (24), together with other transcriptomic studies in azole-
resistant C. glabrata strains (14, 29, 30) and available functional knowledge on
C. glabrata cell wall adhesins, in order to compile a small group of candidate genes for
further testing. They included EPA1, EPA7, EPA12, and PWP4. We performed real-time
quantitative PCR (qPCR) to test the impact of PDR1 hyperactivity on the expression of
these adhesins. Adhesin genes, particularly members of the EPA family, are generally
difﬁcult to target by qPCR due to the presence of tandem repeat sequence regions and
a relatively high sequence similarity between different genes. We retrieved publicly
available C. glabrata adhesin gene sequences from strains CBS138 and BG2 and
sequenced EPA1 from DSY562 and DSY2235. After qPCR optimization, efﬁcient relative
quantiﬁcation of adhesin transcript levels could be achieved, including mutant and
overexpression strains (illustrated for EPA1 in Fig. S3 in the supplemental material). Our
qPCR results revealed that the GOF mutation L280F mediated overexpression (at least
2-fold) of EPA1 in all strain backgrounds (Fig. 2A to D). Other GOF mutations did not
lead to EPA1 overexpression in all strain backgrounds. Strikingly, comparison of tran-
script levels with adherence phenotypes for any given strain revealed a perfect corre-
spondence between EPA1 overexpression and increased adherence to epithelial cells
(Fig. 1B to D and 2A to D). Transcript levels of EPA7 and EPA12 were either increased or
not affected, with no obvious association with increased adherence to epithelial cells.
PWP4 expression was not affected by PDR1 hyperactivity (Fig. 1B to D and 2A to D).
Pdr1 regulates EPA1 expression. The association of EPA1 overexpression with
increased adherence to epithelial cells in C. glabrata strains with PDR1 GOF mutations
ﬁrst indicated a role for EPA1 as a Pdr1-mediated effector of the adherence phenotypes.
Our results showed that PDR1 regulates the expression of EPA1, but the question
FIG 2 Influence of strain background and GOF mutations on PDR1 on selected adhesin transcript levels. Whole-RNA extracts from log-phase C. glabrata
cultures in rich medium were used as the templates to synthesize cDNA. Selected adhesin transcript levels were measured using qPCR with specific
primers and TaqMan probes. Threshold cycles were normalized using RDN5.8 quantification as the internal control. (A) Relative transcript levels of all four
adhesins in DSY562 expressing different PDR1 alleles (strains VSY43, VSY44, VSY132, and VSY133). (B) Relative transcript levels of all four adhesins in
CBS138 expressing different PDR1 alleles (strains VSY215, VSY216, VSY250, and VSY251). (C) Relative transcript levels of EPA1 and EPA7 in BG2 expressing
different PDR1 alleles (strains VSY144 to VSY147). (D) Relative transcript levels of EPA1 and EPA7 in DSY2235 expressing different PDR1 alleles (strains
VSY213 and VSY214).
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remains, however, whether this molecular regulation is direct or indirect. Interestingly,
we noticed the presence of a putative PDRE in the promoter of EPA1 (TCCACGCA,
position starting 571 upstream of the EPA1 start codon [Fig. 3A]) (30) matching the
PDR1 binding site (TCCACGGA) (17). The deletion of 72 bp centered on the putative
PDRE in the EPA1 promoter in a DSY562-derived strain containing the hyperactive
PDR1L280F allele led to expression of EPA1 being decreased by approximately 4-fold
compared to a wild-type EPA1 promoter (Fig. 3B). Interestingly, data published by Paul
et al. (17) reporting the genomic binding sites of Pdr1 suggest that the EPA1 promoter
is targeted by Pdr1 (see Fig. S4A in the supplemental material). Chromatin immuno-
precipitation (ChIP) with anti-Pdr1 on EPA1 showed, however, that Pdr1 does not bind
tightly the EPA1 promoter (see Fig. S4B), thus raising the possibility of an indirect effect
of Pdr1 on EPA1.
PDR1 hyperactivity-mediated increase in adherence to epithelial cells is
dependent on EPA1. The data described above hint at a role for EPA1 in the
FIG 3 Regulation of EPA1 by Pdr1. (A) Schematic illustration of the EPA1 genomic region and localization of the PDRE-like sequence
(TCCACGCA) positioned 563 bp upstream of the EPA1 promoter matching the PDR1 canonical binding site (TCCACGGA). Coordinates of
chromosome E (Chr E) are indicated. (B) Deletion of the PDRE in EPA1 and its effect on EPA1 expression. C. glabrata isolates (VSY21, VSY265,
VSY299, and VSY120) were grown with or without NA limitation as indicated, and EPA1 gene expression was measured with biological
triplicates. The strain lacking the PDRE in the genetic background of DSY565 (hyperactive PDR1L280F; VSY299) was subjected to the same
treatment.
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PDR1-mediated modulation of the interaction of C. glabrata with host epithelial tissues.
In order to conﬁrm this hypothesis, we inactivated EPA1 in DSY562-derived strains and
repeated the competition assays for adherence to epithelial CHO-Lec2 cells. As shown
in Fig. 4A, the absence of EPA1 in DSY562 with a PDR1L280F allele eliminated the
FIG 4 Influence of PDR1 hyperactivity and EPA1 on the interaction of C. glabrata with epithelial cells.
Confluent CHO-Lec2 epithelial cell monolayers were infected with suspensions containing a 1:1 mix
of log-phase C. glabrata strains with either the PDR1WT or the PDR1L280F allele in the presence or
absence of EPA1. The cocultures were incubated for 30 min at 37°C in a humid atmosphere with 5%
CO2 and then washed to remove nonadherent yeasts. The epithelial cells were selectively lysed, and
dilutions of the resulting yeast suspensions were plated on solid medium with or without fluconazole
(to distinguish between azole-susceptible and azole-resistant yeast strains). Results are presented as
CFU counts relative to the strain bearing the PDR1WT allele (set to 100%). (A) Adherence of
DSY562-derived strains (VSY101, VSY102, VSY244, and VSY266). (B) Adherence of DSY562-derived
strains (VSY101, VSY102, and VSY293) grown either in complete medium or under adhesion-inducing
NA limitation. (C) Adherence of DSY2235-derived strains (VSY229, VSY230, and VSY287). Results are
means  standard deviations of a minimum of three independent experiments. Pairwise compari-
sons were performed using unpaired-sample two-tailed Mann-Whitney U tests. Bonferroni-adjusted
P values of <0.05 were considered significant, and asterisks represent P value ranges (*, P value of
<0.05; **, P value of <0.01). WT, wild type; ns, not significant.
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increased adherence compared to the strain harboring a wild-type PDR1 allele. This
epa1Δ strain showed no difference in adherence to epithelial cells from the strain
harboring the wild-type EPA1 and PDR1 alleles. Reversion of EPA1 rescued the increase
in adherence (Fig. 4A). C. glabrata is often found causing infection in nicotinic acid
(NA)-deﬁcient host environments (notably in the urinary tract). This host niche is known
to lead to derepression of EPA1 and other subtelomeric adhesin genes (8), thus
signifying that EPA1 can be upregulated even in the absence of PDR1 GOF mutations.
We recapitulated this situation by addressing adherence of C. glabrata grown either in
complete medium or in NA-limited medium (5% of the regular NA concentration).
When the wild type was grown under NA limitation, i.e., PDR1-independent adhesin
expression-inducing conditions (as shown by qPCR for EPA1 [see Fig. S5 in the supple-
mental material]), adherence to epithelial cells matched that of the strain with the
hyperactive PDR1L280F allele grown under a normal NA concentration (Fig. 4B). Never-
theless, the increased adherence mediated by PDR1 hyperactivity was still detected
when both strains were grown under NA limitation (Fig. 4B). Taken together, our data
conﬁrm that EPA1 mediates the difference in adherence between C. glabrata strains
with wild-type and hyperactive PDR1 alleles.
Impact of EPA1 on adherence to epithelial cells is C. glabrata strain de-
pendent. Inactivation of EPA1 in DSY562 with the hyperactive PDR1L280F allele had an
unexpectedly low impact on adherence to epithelial cells (reduction of adherence by
less than 30%), thus making it almost indistinguishable from the wild type. Inactivating
EPA1 in DSY562 had a similar low impact on adherence (Fig. 4A). This suggests that
EPA1 was not required to maintain basal adherence levels in this strain. This is in
contrast to the large adherence reduction (90%) reported previously in BG2 (7). We
tested the BG2 epa1Δ strain and observed the same large reduction in adherence (data
not shown), thus ruling out inappropriate test conditions. This suggests an inherently
low contribution of Epa1 for basal adherence of DSY562 to epithelial cells. We then
inactivated EPA1, tested the adherence of DSY2235 containing the hyperactive
PDR1L280F allele, and compared the results to the wild type. Adherence of the DSY2235
epa1Δ mutant dropped by more than 75% compared to the wild type (Fig. 4C),
reminiscent of observations in BG2. While performing these experiments, we noticed
that basal EPA1 expression levels were highly variable between different C. glabrata
strain backgrounds. Interestingly, these basal expression levels were proportional to the
degree of adherence to epithelial cells. However, our results indicated that DSY562
stands as an exception. Even if this yeast expresses EPA1 at the lowest levels among the
tested isolates of this study, it was still second in terms of adherence to epithelial cells
(Fig. 5). This, together with the low impact of EPA1 on adherence, suggests that, unlike
other C. glabrata strains (which rely heavily on Epa1 for adherence to epithelial cells),
the DSY562 strain background relies primarily on alternative adhesins for basal adher-
ence. Nevertheless, and even if PDR1 hyperactivity mediates upregulation of additional
adhesins in DSY562, PDR1 hyperactivity still mediates increased adherence to epithelial
cells through EPA1 upregulation in this strain background.
PDR1 hyperactivity mediates an EPA1-dependent increase in colonization
of the murine urinary tract. In order to determine the biological signiﬁcance of
PDR1-mediated regulation of EPA1 expression, we employed a murine model of urinary
tract infection (UTI). Besides strains expressing either PDR1WT or PDR1L280F and epa1Δ
strains, we also addressed the impact of PDR1-independent EPA1 overexpression. To
this end, we constructed DSY562-derived strains expressing EPA1 from an episomal
plasmid under the control of a strong constitutive promoter (the Saccharomyces
cerevisiae PGK1 [ScPGK1] promoter). The resulting strains displayed a strong increase in
EPA1 transcript levels, irrespective of the PDR1 allele (see Fig. S6A in the supplemental
material). This was accompanied by an increase in the measured adherence to epithelial
cells to close to 100% of the inoculum under our test conditions (see Fig. S6B). We
tested all these genetic variants from the DSY562 strain background in the UTI model,
as well as a subset of them in the DSY2235 strain background. The results illustrate an
increased ability of strains expressing PDR1L280F to colonize the bladder and then to
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reach the kidneys of infected mice compared to strains with PDR1WT (Fig. 6A to D). Just
as in the case of adherence to epithelial cells, these phenotypes depended on EPA1,
since PDR1L280F epa1Δ strains showed CFU counts indistinguishable from those of the
PDR1WT strains in both DSY562 and DSY2235. The ScPGK1 promoter-driven EPA1
overexpression in DSY562 led to the highest observed CFU counts, with no statistically
signiﬁcant difference between PDR1 alleles (Fig. 6A and C). With regard to epa1Δ
mutants in DSY562 with PDR1L280F, even if they show a decrease in tissue burden in
infected animals, they still show a higher burden than the epa1Δ PDR1WT strain. This
suggests an additional, EPA1-independent effect of PDR1 hyperactivity in the coloni-
zation of host urinary tract organs by C. glabrata.
DISCUSSION
Effect of PDR1 on EPA1 expression. We have previously established a link between
PDR1 hyperactivity and enhanced virulence in C. glabrata with mouse models of
infection (12). A follow-up work showed that a decreased phagocytosis by macro-
phages and an increased adherence to host epithelial cells contribute to these phe-
notypes (25). Here, we report that regulation of these phenotypes by PDR1 seems to be
complex. PDR1 hyperactivity per se does not guarantee differences in the interactions
with host cells, which additionally depend on the C. glabrata genetic background and
speciﬁc PDR1 GOF mutations. Changes in phagocytosis by macrophages depend on the
C. glabrata strain background, as phagocytosis of two of the four tested strains was not
affected by replacement of the wild-type PDR1 allele by PDR1L280F. Further work will be
required to explain this observation. The interaction with epithelial cells, on the other
hand, was affected in all strain backgrounds but depended on the speciﬁc GOF
mutation. GOF mutations have profound and distinct effects on the C. glabrata tran-
scriptome, and not all GOF mutations will lead to upregulation of EPA1 (24). Until now,
the molecular basis behind the transcriptome heterogeneity due to PDR1 GOF muta-
tions has not been elucidated. Among possible explanations, PDR1may recruit different
cofactors or additional zinc cluster transcriptional regulators to form heterodimers,
which may depend on the type of GOF mutation, thus shaping differences in target
binding domains. On the other hand, PDR1 may be subjected to selective degradation
(for example, ubiquitylation) with different kinetics depending on the nature of GOF
mutations, thus creating distinct transcriptional complexes and distinct transcriptional
proﬁles. Transcriptional control by ubiquitylation is known for yeast transcription
factors and especially when they are in an active state (31). Last, PDR1 is known to
interact with subunits of the Mediator complex, which is composed of a sophisticated
FIG 5 Comparison of the influence of PDR1 hyperactivity on EPA1 expression and the interaction of
C. glabrata with epithelial cells in different strain backgrounds. Experiments were performed as
detailed above in Fig. 1 and 2, with the same C. glabrata strains. The horizontal axis shows CFU
counts as percentages of the inoculated CFU adhering to CHO-Lec2 epithelial cell monolayer
experiments. The vertical axis shows EPA1 transcript levels relative to DSY562 expressing the PDR1WT
allele. Results are means  standard deviations of a minimum of three independent experiments.
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architecture of proteins (32). Speciﬁc GOF mutations may interfere with the Mediator
complex and alter transcription speciﬁcity and efﬁciency. Our data conﬁrm that GPI-
modiﬁed cell wall adhesin genes are part of the PDR1 extensive regulon and show that
PDR1 modulates the interaction with epithelial cells through the transcriptional regu-
lation of adhesins, among which EPA1 was found to play a major role. In fact, increased
adherence to epithelial cells in strains with hyperactive PDR1 alleles strictly depends on
EPA1. The question of whether EPA1 regulation by PDR1 is direct or indirect remains
open. While deleting the putative PDRE on the promoter of EPA1 resulted in a decrease
in EPA1 expression, chromatin immunoprecipitation (ChIP) experiments failed to detect
a direct binding of Pdr1 to the EPA1 promoter. It is possible that the subtelomeric
location of EPA1 makes Pdr1 difﬁcult to access experimentally, due to the presence of
other factors that are part of the subtelomeric silencing complex. These factors include
Sir2 and other members (HST1 to -4) of the bulky subtelomeric silencing protein
complex (33). This might conceivably lead to a false-negative ChIP result, but more
evidence is required to solve this question. SIR2 downregulation is known to mediate
derepression of EPA1 (33). Genome-wide microarray data previously gathered by our
laboratory did not involve SIR2 downregulation in DSY565 (the clinical strain containing
the PDR1L280F allele) as a possible mediator of increased EPA1 expression in azole-
resistant isolates (24). As we mentioned above, PDR1 may recruit the ubiquitylation
FIG 6 Influence of PDR1 hyperactivity and EPA1 on the colonization of the bladder and kidney by C. glabrata in the
murine urinary tract infection (UTI) model. Experimental details are given in Materials and Methods. C. glabrata burdens
in bladders and kidneys are presented as CFU/gram of organ (bars are geometric means). (A) Bladder burdens of
DSY562-derived strains: SFY114, SFY115 (results confirmed using DSY562 and DSY565; data not shown), VSY271, VSY272,
VSY220, and VSY221. (B) Bladder burdens of DSY2235-derived strains: VSY229, VSY230 (results confirmed using VSY213
and VSY214; data not shown), and VSY287. (C) Kidney burdens of DSY562-derived strains (same strains as in panel A). (D)
Kidney burdens of DSY2235-derived strains (same strains as in panel B). Pairwise comparisons were performed using
unpaired-sample two-tailed Mann-Whitney U tests. Bonferroni-adjusted P values of <0.05 were considered significant,
and asterisks represent P value ranges (*, P value of <0.05; **, P value of <0.01). ns, not significant.
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machinery, which itself might be able to modify histones and therefore inﬂuence
subtelomeric silencing and consequently EPA1 expression. Ubiquitylation as an indirect
regulatory mechanism was described in S. cerevisiae for ubiquitin-conjugating enzyme
Rad6 and the histone H2B (34). This working model is under investigation in our
laboratory.
Challenges in addressing EPA1 expression. Adhesins have been notably absent
from previous genome-wide studies of the Pdr1 regulon generally focused on analysis
of azole drug resistance. The reason for this may be that adhesin genes are particularly
difﬁcult to analyze. Adhesin genes are characterized by the presence of megasatellites
(tandemly repeated sequences with variable size), high intraspecies sequence variabil-
ity, and high intergenic sequence similarity within the EPA family (35). These charac-
teristics make these genes difﬁcult to analyze in genome-wide transcriptional studies.
In previous microarray experiments, EPA gene transcript signals may have been largely
undetected and/or amalgamated with different transcript signals in the same family. A
notable exception is the study by Caudle et al. (30), in which EPA1 was upregulated by
a speciﬁc PDR1 GOF mutation (K274N). Interestingly, this work also highlighted a
second PDR1 GOF mutation (L946S), which did not result in EPA1 upregulation and was
thus in agreement with our observations on the different effects of GOF mutations on
EPA1 expression. Even in RNA sequencing experiments, adhesin genes may pose
important challenges to mapping of short reads, which may exclude them from further
analysis during quality control steps. Previous studies by the Cormack laboratory have
mostly relied on radioactive probe-based S1 nuclease protection assay for speciﬁc and
sensitive relative quantiﬁcation of EPA1 transcript levels (8, 28, 36, 37). Here, we have
developed and used an alternative qPCR method. We have used strains harvested in
mid-log phase following dilution of overnight saturated cultures and grown for two
generations in rich medium. Testing EPA1 expression under these conditions requires
a strict attention to growth conditions to ensure reproducibility. This is especially
relevant since EPA1 expression changes rapidly during in vitro growth. It is transiently
induced upon dilution in fresh growth medium under standard laboratory growth
conditions and is then transcriptionally repressed by subtelomeric silencing (28).
C. glabrata genetic backgrounds and EPA1-related phenotypes. EPA1 has
long been considered the major adhesin of C. glabrata, enabling most of the capacity
for adherence to epithelial cells, even though C. glabrata contains more than 20
EPA-like genes and other types of adhesin-like genes (6). We showed here that
virulence-enhancing PDR1 hyperactivity depends on EPA1 to mediate increased adher-
ence to epithelial cells. There are intraspecies differences in homogeneity of EPA1
expression. Two C. glabrata groups of isolates have been identiﬁed, including the
CBS138-like group of strains, in which EPA1 expression is homogeneous in yeast cell
populations, and BG2-like strains, in which expression varies between individual cells
(38). These patterns also seem to be associated with differences in expression ratios
between noninducing and inducing (NA limitation) conditions (38). DSY562 belongs to
the CBS138-like group, as it shows homogeneous expression (data not shown). In this
work, we also noticed intraspecies differences in basal levels of EPA1 expression:
transcript levels are highly variable between different C. glabrata strains (Fig. 5).
Furthermore, there is yet another layer of complexity, since some C. glabrata strains are
independent of EPA1 for their high basal adherence to epithelial cells. While BG2 and
DSY2235 depend almost exclusively on EPA1 for adherence, DSY562 displays basal
adherence levels independent of EPA1. In the DSY562 background, EPA1 plays a role
only in increased adherence. We have indications that the DSY562 genome contains a
higher number of adhesin genes than BG2 or CBS138 (L. A. Vale-Silva and D. Sanglard,
unpublished data). This feature may explain the relatively low dependence of this strain
on EPA1. Interestingly, a recent study showed that C. glabrata isolates of clinical origins
may harbor distinct patterns of cell wall adhesins contributing to the intrinsic adher-
ence capacities of such strains (39). This reinforces the notion that C. glabrata isolates
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may differ between each other in their repertoire of adhesins by either differential
expression and/or the presence of distinct genomic patterns.
Relevance of EPA1 in the UTI model. We conﬁrmed using the UTI model that
EPA1 is important for in vivo colonization of the bladder and kidneys. It is also crucial
for PDR1-mediated increased colonization. This likely contributes to enhanced viru-
lence. Previous data from the Cormack laboratory found no inﬂuence of an epa1Δ
mutant in a vaginal and gastrointestinal infection model (7, 40). Later, the same
laboratory found lower colonization of the mouse bladder by a mutant lacking three
adhesion genes, including EPA1, EPA6, and EPA7 (8, 40). We observed here that the
single EPA1 deletion is sufﬁcient for decreasing C. glabrata fungal loads in the UTI
mouse model. One reason for this discrepancy could be due to differences in genetic
backgrounds of the investigated yeasts (BG2 versus DSY562/2235) and/or of the mice.
It is likely that several other adhesins may play a role in vivo rather than in vitro. For
example, deletion of EPA1 in DSY2235 has a higher impact on adherence in vitro than
on bladder/kidney colonization in vivo. On the other hand, overexpressing EPA1 alone,
even in the presence of PDR1WT, is enough to increase CFU to levels that may even
reach saturation of the model.
In conclusion, we found that some adhesins, including EPA1, are regulated by PDR1.
Elevated expression of EPA1 is the major mechanism that leads to increased adherence
to epithelial cells in strains bearing hyperactive PDR1 alleles. EPA1 has a clear impact in
vivo and allows colonization of the bladder and kidneys in the UTI murine model. EPA1
is likely to be an important contributor to increased virulence of azole-resistant
C. glabrata strains with GOF PDR1 alleles as we earlier published.
MATERIALS AND METHODS
C. glabrata strain culture and growth media. All C. glabrata strains used in this study are listed in
Table S1 in the supplemental material. Strains with the preﬁx SFY are from previously published
collections (12, 24). All strains were stored in 20% glycerol stocks at 80°C and cultured in either YPD
(1% yeast extract, 2% peptone, 2% D-glucose) rich medium or appropriate selective media at 30°C. For
solid media, 2% agar was added. Selective medium for growth of transformed strains was YPD containing
either 200 g/ml of nourseothricin (clonNAT; Werner BioAgents, Germany) or 600 g/ml of hygromycin
B (PAA Laboratories, Austria). Additionally, YNB minimal medium (0.67% yeast nitrogen base plus 2%
glucose) with appropriate amino acids and bases and without uracil was used to select uracil pro-
totrophs. To obtain sensitive derivatives after recycling of the dominant selection marker cassettes,
resistant strains were incubated for a minimum of 4 h in YCB-BSA medium (23.4 g/liter yeast carbon base
and 4 g/liter bovine serum albumin; pH 4.0), and between 100 and 200 CFU was plated on YPD agar
plates containing either 20 g/ml of nourseothricin or 200 g/ml of hygromycin B. YPD containing
30 g/ml of ﬂuconazole (Sigma) was used when required. Escherichia coli DH5 was used as a host for
plasmid construction and propagation. E. coli DH5 was grown in Luria-Bertani broth or on Luria-Bertani
agar plates, supplemented with 0.1 mg/ml of ampicillin (AppliChem GmbH, Germany) when required.
Plasmids and C. glabrata strain constructions. All yeast transformations were performed using an
adapted lithium acetate (LiAc) procedure (41). Strains expressing ﬂuorescent proteins were constructed
using targeted gene disruption of CgURA3, followed by transformation with episomal plasmids comple-
menting uracil auxotrophy as previously described (25). Inactivation of URA3 in the DSY2235 strain
background led to a detectable growth defect even after episomal URA3 complementation. There was
no difference between strains expressing different PDR1 alleles and different ﬂuorescent proteins (see
Fig. S1 in the supplemental material). Other strain backgrounds had no detectable change after deletion
of URA3.
PDR1 deletion and replacement of PDR1 alleles were performed using the recyclable dominant
selection marker SAT1 (42), encoding nourseothricin resistance (SATr) as previously described (12).
EPA1 deletion strains were constructed by targeted gene disruption of EPA1 using recyclable
dominant selection markers. A recyclable marker based on the hph gene from Klebsiella pneumoniae,
encoding hygromycin B resistance (Hygr) (8), was designed to use with SATr strains. To construct this
plasmid, the hph expression cassette (FLP recombination target [FRT]-ScPGK1p-hph-3’ untranslated
region [UTR] ScHIS3-FRT) was ampliﬁed by PCR from plasmid pAP599 (8), a gift from Brendan Cormack
(Johns Hopkins University), using primers HygR-BlpI (5=-GGCCGCTTAGCGAGAAAGAAATTACCGTC-3=) and
HygR-NotI (5=-GTCGGCGGCCGCGATAAGCTTGAAGTTC-3=). The amplicon was inserted into BlpI/NotI-
digested pSFS1A, a gift from Joachim Morschhäuser (Universität Würzburg), in order to replace the
SAT1-expressing section of the SAT1 ﬂipper, thus generating pVS31. To construct the EPA1 disruption
cassettes, the complete EPA1 open reading frame (ORF) ﬂanked by 500 bp was ampliﬁed by PCR from
genomic DNA of DSY562 using primers EPA1-KpnI (5=-TCAAGGTACCTACTAAGGTTCCATGGCTG-3=) and
EPA1-SacII-2 (5=-CCTACCGCGGTTTCTTTTCACCTGAAAGATTAC-3=). The resulting PCR product was inserted
into pBluescript II KS() to generate pVS33. This plasmid was ampliﬁed by PCR using primers EPA1-XhoI
(5=-AAATCTCGAGAATGAAGAAAAAGCTTTGTGAAGGC-3=) and EPA1-NotI (5=-CATAGCGGCCGCAAACCAGG
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AAATATAATAACTTCC-3=). The resulting PCR product was digested by XhoI and NotI and ligated to
XhoI/NotI fragments from either pSFS1A or pVS31. The resulting plasmids pVS34 (SAT1 ﬂipper-based
EPA1 deletion cassette) and pVS37 (hph-based EPA1 deletion cassette) were digested by SacII and KpnI
or SacI and KpnI, respectively, and used to transform C. glabrata strains.
To construct the EPA1 reversion cassette, the EPA1 ORF ﬂanked by 500 bp and 1 kb was ampliﬁed by
PCR from DSY562 genomic DNA using primers EPA1-KpnI (5=-TCAAGGTACCTACTAAGGTTCCATGGCTG-3=)
and EPA1-SacII-3 (5=-TGCTCCGCGGCCATGAGATTATCTTCTTGAAAG-3=) and inserted into pBluescript II
KS() to generate pVS42. This plasmid was ampliﬁed by PCR using primers 3= UTR-EPA1-NotI (5=-AAA
AGCGGCCGCGTTAGGCTTATTAGAACCAG-3=) and 3= UTR-EPA1-XhoI (5=-CTAACTCGAGTTCTTTTCACCTGA
AAGATTAC-3=), digested by XhoI and NotI, and ligated to the XhoI/NotI fragment from pSFS1A, thus
generating pVS43. The resulting plasmid was digested by SacII and KpnI and used to transform
C. glabrata strains. Recycling of the SAT1 ﬂipper reconstitutes the native 3=-ﬂanking region of the gene,
leaving only one 34-bp ﬂippase recombination target (FRT) sequence at about 600 bp downstream of the
stop codon.
To construct EPA1 overexpression strains, the complete EPA1 ORF was ampliﬁed by PCR from DSY562
genomic DNA, using primers EPA1-XbaI (5=-CCAATCTAGAACAATGATTTTAAATCCAGCTC-3=) and EPA1-
XhoI-2 (5=-AATGCTCGAGTATGGAAGTTATTATATTTCCTGG-3=), digested by XbaI and XhoI, and ligated to
a XbaI/XhoI fragment from vector pGRB2.3 (43). This generated pVS39, which is episomal (CgCEN/ARS)
and contains URA3. It contains the EPA1 overexpression cassette (ScPGK1p-EPA1-ScHIS3) replacing the
yEGFP gene from the parent pGRB2.3. The same vector containing only the promoter and the terminator,
pVS20 (25), was used as the parent control plasmid. The nondigested plasmids were used to transform
ura3Δ C. glabrata strains. Transformants were selected on YNB lacking uracil.
To delete the putative PDRE on positions 571 to 564 relative to the EPA1 start codon (a possible
Pdr1 binding site), a 1-kb EPA1 5=-ﬂanking sequence was ampliﬁed by PCR using primers EPA1-KpnI-2
(5=-GCAGGGTACCAAAAAGAACATC-3=) and EPA1-NcoI (5=-GTCACCATGGAATAGAGTGGATCTGGTACTTTG-
3=). The PCR product was digested by KpnI and NcoI and ligated to a KpnI/NcoI fragment from pVS43,
thus generating pVS47. This makes use of a naturally occurring NcoI restriction site 35 bp downstream
of the putative PDRE and generates a plasmid carrying a deletion of 72 bp (between positions 600 and
527) centered on the putative PDRE on the 5= UTR of EPA1. pVS47 was digested by SacII and KpnI and
used to transform epa1Δ C. glabrata strains.
All constructed plasmids were conﬁrmed by DNA sequencing. Constructed strains were conﬁrmed by
sequencing or PCR. EPA1 deletions and reversions were conﬁrmed by Southern blotting (data not
shown).
Epithelial cell and macrophage cultures. Mammalian cell lines were cultured at 37°C in a humid
atmosphere with 5% CO2. Chinese hamster ovary cell lines Lec2 (CHO-Lec2; ATCC CRL1736) and AA8
(CHO-AA8; CRL-1859) were cultured in complete minimum essential medium  (MEM-): high-glucose
minimum essential medium  (Life Technologies, Zug, Switzerland) with L-glutamine and supplemented
with 100 U/ml penicillin, 100 g/ml streptomycin (Life Technologies), and 10% fetal bovine serum (FBS)
(Life Technologies). Human cervix adenocarcinoma cells (CHO-HeLa; ATCC CCL-2), human colorectal
adenocarcinoma cells (Caco-2; ATCC HTB-37), and mouse rectum polyploidy carcinoma cells (CMT-93;
ATCC CCL-223) were cultured in complete Dulbecco’s modiﬁed Eagle’s medium (DMEM): high-glucose
Dulbecco’s modiﬁed Eagle’s medium with GlutaMAX (Life Technologies), supplemented with 100 U/ml
penicillin and 100 g/ml streptomycin (Life Technologies) and 10% fetal bovine serum (FBS; Life
Technologies). Abelson murine leukemia virus-induced tumor macrophage-like cells (RAW 264.7; ATCC
TIB-71) were also routinely cultured in complete DMEM.
Phagocytosis assays. Competition phagocytosis assays were performed as previously described
(25). Brieﬂy, harvested bone marrow-derived macrophages (BMDMs) were suspended in complete Iscove
modiﬁed Dulbecco medium (IMDM) at a density of 3.0  105 cells/ml. RAW 264.7 macrophage-like cells
were suspended in complete DMEM at a density of 1.0  105 cells/ml in complete IMDM. Macrophage
suspensions were transferred to 24-well plates in a volume of 1 ml per well on top of round cover slides
and incubated overnight at 37°C in a humid atmosphere with 5% CO2. Macrophages were then infected
with 1:1 mixtures of 3.0  105 yeast cells of each of the two C. glabrata strains in 100 l of
phosphate-buffered saline solution (PBS). The plates were centrifuged for 1 min at 200  g and
incubated for 30 min at 37°C in the presence of 5% CO2. Cocultures were washed to remove non-
macrophage-associated yeasts, and the round cover slides with adherent cells were stained with
100 g/ml of calcoﬂuor white for 10 min. The cover slides were mounted onto microscopy slides and
observed using a Zeiss Axioplan 2 epiﬂuorescence microscope. Images were recorded using a Visitron
Systems HistoScope camera and VisiView imaging software (Visitron Systems, Puchheim, Germany).
Yeast adherence to epithelial cells. Adherence to epithelial cells was tested using our protocol (25)
adapted from a previously published assay (7). Brieﬂy, log-phase epithelial cells were seeded in 24-well
plates at a density of 1.0  105 cells/well in 1 ml of culture medium and allowed to grow to full
conﬂuence at 37°C in a humid atmosphere with 5% CO2, typically for 48 to 72 h. To prepare C. glabrata
suspensions for infection, overnight cultures of test strains were diluted in fresh medium and grown for
a minimum of two generations to mid-log phase. For nicotinic acid limitation experiments, yeast strains
were grown either in complete YNB minimal medium (0.67% yeast nitrogen base plus 2% glucose) with
appropriate amino acids and bases or in the same medium containing only 5% of the normal nicotinic
acid concentration (nicotinic acid limitation). Log-phase cultures were washed and resuspended in PBS.
Epithelial cell monolayers were infected with 1:1 mixed yeast suspensions containing 3.0  105 yeast
cells, and the plates were centrifuged at 200 g for 1 min. Cocultures were incubated at 37°C in a humid
atmosphere with 5% CO2 for 30 min, and nonadherent yeasts were removed by washing. Adherent
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yeasts were recovered by lysis of the epithelial cells in 0.1% Triton X-100 and plated onto YPD agar plates
for quantiﬁcation of CFU. YPD agar alone and YPD agar plates containing 30 g/ml of ﬂuconazole were
used to distinguish between azole-susceptible and azole-resistant yeast strains.
qPCR. Total RNA was extracted from log-phase cultures in 5 ml of YPD broth by mechanical
disruption of the cells with glass beads as previously described (44). Total RNA extracts were treated with
DNase using the DNA-free kit (Ambion-Life Technologies, Zug, Switzerland), and 1 g of RNA was used
as a template to synthesize cDNA using the Transcriptor high-ﬁdelity cDNA synthesis kit (Roche
Diagnostics, Rotkreuz, Switzerland). For relative quantiﬁcation of the target genes, real-time quantitative
PCRs (qPCRs) were performed using sets of primers and TaqMan probes with the iTaq Supermix with ROX
(Bio-Rad Laboratories AG, Cressier, Switzerland) in a StepOnePlus real-time PCR system (Applied
Biosystems-Life Technologies, Zug, Switzerland). The speciﬁc primers and probe used for the target gene
EPA1 were EPA1a (5=-ACCGCAAGAAAATCCTCCTCC-3=), EPA1b (5=-TGGTGCTGATGATATTGATTTGTTG-3=),
and EPA1pr (6-carboxyﬂuorescein [FAM]–5=-TGGCCTCCATTCATACCCCACTTCCA-3=–6-carboxytetramet
hylrhodamine [TAMRA]). The speciﬁc primers and probe used for the target gene EPA7 were EPA7a
(5=-TGATTTACGGAAGAATGGTTCG-3=), EPA7b (5=-TTACCGGTAACACCATCAACT-3=), and EPA7pr (6-FAM–
5=-TGGGATCTAAATATGCGGCATCCCAACA-3=–TAMRA). The speciﬁc primers and probe used for the target
gene EPA12 were EPA12a (5=-AAGGGTTTGTCAATGGAACTG-3=), EPA12b (5=-CACCCTTGGAAAATTCGGAT
C-3=), and EPA12pr (6-FAM–5=-TCGGAAGAAAGGTTCTCACCCATGCT-3=–TAMRA). The speciﬁc primers and
probe used for the target gene PWP4 were PWP4a (5=-GAGTAGATCTAGAACTGCGGG-3=), PWP4b (5=-AG
TGATCAACTGGGAACTACC-3=), and PWP4pr (6-FAM–5=-ACCCAGCCCTGCAGTGAGTACTCT-3=–TAMRA).
The internal control gene was RDN5.8, using previously published oligonucleotides (45): RDN5.8-F
(5=-CTTGGTTCTCGCATCGATGA-3=), RDN5.8-R (5=-GGCGCAATGTGCGTTCA-3=), and RDN5.8-Pr (6-FAM–5=-
ACGCAGCGAAATGCGATACGTAATGTG-3=–TAMRA). At least three biological replicates were included, and
each reaction was run in duplicate. Changes (n-fold) in gene transcription levels relative to an included
reference C. glabrata strain were determined from RDN5.8-1-normalized threshold cycle (CT) values. A
2-fold increase in transcript level was arbitrarily considered signiﬁcant.
UTI model. Urinary tract infection (UTI) experiments were performed according to a previously
described model (46). Brieﬂy, for tissue burden experiments, each C. glabrata strain was grown in 10 ml
of YPD broth under agitation for 18 h at 37°C. After growth, cells were centrifuged, washed and
resuspended in 10 ml of sterile PBS, and then adjusted to reach a concentration of 5  108 cells/ml. For
each strain, a group of 10 isoﬂurane-anesthetized female BALB/c mice were infected via intraurethral
catheterization (polyethylene catheter, about 4 cm long; outer diameter, 0.61 mm; Becton, Dickinson,
Sparks, MD) using 100 l of the corresponding C. glabrata cell suspension for each animal. Mice were
sacriﬁced 7 days after the transurethral challenge, and for each animal, bladders and kidney pairs were
harvested, weighed, and homogenized in 1 and 5 ml of sterile saline, respectively. C. glabrata inocula and
burdens were enumerated by performing serial dilutions and counting CFU on YPD agar. The C. glabrata
detection limits were 50 and 10 CFU/ml for kidneys and bladder homogenates, respectively. CFU counts
were analyzed by unpaired t tests, and a P value of less than 0.05 was considered signiﬁcant.
Nucleotide sequence accession numbers. The EPA1 gene sequences of C. glabrata strains DSY562
and DSY2235 determined in the present study have been deposited in GenBank under accession
numbers KR296804 and KR296805, respectively.
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